AstraZeneca Pharma India Reports 30% Revenue Growth, Crosses Rs 7,291 Mn
Article excerpt
Highlighted: the sentence this signal was extracted from
Strong performance across oncology, biopharmaceuticals and rare diseases, alongside regulatory approvals and state-level healthcare partnerships, drives growth AstraZeneca Pharma India Limited reported a 30 per cent year-on-year growth in revenue from operations to Rs 7,291 million in the second quarter of FY2026-27, covering July to September 2026, driven by sustained performance across its oncology, biopharmaceuticals and rare disease portfolios. The company also reported a 30 per cent increase in revenue for the first half of FY2026-27, reaching Rs 14,119 million, compared with Rs 10,854 million in the corresponding period last year. The company attributed its performance to operational efficiency, portfolio expansion and increasing adoption of innovative therapies addressing unmet medical needs in India. Oncology remained the largest contributor, generating Rs 5,085 million in Q2, compared with Rs 3,978 million in the year-ago quarter. Revenue from biopharmaceuticals, covering cardiovascular, renal and metabolism (CVRM), respiratory and immunology (R&I), and vaccines and immunotherapies (V&I), stood at Rs 1,610 million, against Rs 1,268 million previously. The rare diseases segment recorded revenue of Rs 204 million, compared with Rs 38 million in the corresponding quarter last year. Regulatory Approvals And Expansion Commenting on the results, Praveen Rao Akkinepally...
Keep reading with a free account
The rest of this article, and every signal for AstraZeneca, is in your free account.
